Rational combination of cancer therapies with PD1 axis blockade

IF 72.5 1区医学 Q1 ONCOLOGY

Nature Reviews Cancer Pub Date : 2024-07-30 DOI:10.1038/s41568-024-00727-1

引用次数: 0

Abstract

This poster explores rational combinations of immune checkpoint blockade of the PD1–PDL1 interaction with other therapies aimed at targeting effector T cells, innate immune and regulatory cells, the tumour microenvironment and cancer cells.

查看原文本刊更多论文

癌症疗法与 PD1 轴阻断剂的合理组合

本海报探讨了免疫检查点阻断 PD1-PDL1 相互作用与其他疗法的合理组合，这些疗法旨在靶向效应 T 细胞、先天性免疫和调节细胞、肿瘤微环境和癌细胞。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Cancer 医学-肿瘤学

CiteScore

111.90

自引率

0.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cancer, a part of the Nature Reviews portfolio of journals, aims to be the premier source of reviews and commentaries for the scientific communities it serves. The correct abbreviation for abstracting and indexing purposes is Nat. Rev. Cancer. The international standard serial numbers (ISSN) for Nature Reviews Cancer are 1474-175X (print) and 1474-1768 (online). Unlike other journals, Nature Reviews Cancer does not have an external editorial board. Instead, all editorial decisions are made by a team of full-time professional editors who are PhD-level scientists. The journal publishes Research Highlights, Comments, Reviews, and Perspectives relevant to cancer researchers, ensuring that the articles reach the widest possible audience due to their broad scope.